Pharmacologic class (EPC) · 2 drug pages

Parathyroid hormone analog: adverse event reports filed with FDA

106,260 reports list a drug in this class as a suspect or interacting product, 2004–2026.

Read first · FDA's statement on these data

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product. openFDA, FDA

FDA adds: "There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event." The information in these reports "cannot be used to estimate the incidence of these events."

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

106,260
reports across the class: 0.5% of all reports; 1,837
reports, 12 months to June 2026: 1,565 in the 12 months before; 36.5%
marked serious by the reporter: 57.4% across all reports; 2
drugs with a page: brand and generic names counted separately

Parathyroid hormone analog is a pharmacologic class (an FDA Established Pharmacologic Class) with 2 drug pages on this site. Together those drugs are listed as a suspect or interacting product in 106,260 adverse event reports received by FDA, 0.5% of the database, from January 2004 to June 2026.

1,837 reports arrived in the 12 months to June 2026, up 17% from 1,565 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. 36.5% of the class's reports are marked serious, 4.7% record death among the outcomes and 21.3% record hospitalisation, as reported.

Across the class the reactions recorded most often are nausea (8.1%), arthralgia (7.9%) and pain in extremity (7.6%). The class median share shown beside each term is the middle value across the member drugs; it is the comparison used on every drug page in this class.

The members table is ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Drugs in the class

Drug	Name type	Reports	Latest 12 months	Marked serious	Top term recorded
ForteoTeriparatide	brand	100,285	479	34.6%	Nausea
Teriparatide	generic	5,975	1,358	68.7%	Dizziness

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Reports by month, five years

FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

Reactions recorded across the class

share of class reports recording the termmedian drug in the class

Nauseafeeling sick8.1%8,570
Arthralgiajoint pain7.9%8,348
Pain in extremitypain in an arm or leg7.6%8,035
Dizzinesslight-headedness or unsteadiness7.5%7,927
Falla fall7.1%7,576
Painpain, site not specified6.8%7,200
Fatiguetiredness6.4%6,805
Back painback pain5.3%5,668
Muscle spasmsmuscle cramps5.3%5,625
Malaisegeneral feeling of being unwell5.2%5,508
Headachehead pain4.9%5,175
Astheniaweakness or lack of energy4.9%5,173
Injection site erythemaredness where the injection was given4.5%4,801
Injection site bruisingbruising where the injection was given4.5%4,739
Injection site painpain where the injection was given4.3%4,603
Injection site haemorrhagebleeding where the injection was given3.9%4,174
Feeling abnormalfeeling odd or not right3.9%4,107
Bone painbone pain3.8%3,988
Drug dose omissiona dose was missed3%3,221
Deaththe patient died; cause not stated by this term2.7%2,852
Gait disturbancedifficulty walking2.5%2,709
Myalgiamuscle pain2.3%2,452
Constipationconstipation2.3%2,413
Diarrhoealoose or frequent stools2.3%2,413
Dyspnoeashortness of breath2.2%2,360

Solid bar: share of all class reports. Hollow bar: the median share across the 2 member drugs, the reference used on each member's page. One report can record several terms.

Outcomes, patients and reporters

Outcomes recorded

Death4.7%4,994

Life-threatening0.5%565

Hospitalisation (initial or prolonged)21.3%22,682

Disability0.7%759

Congenital anomaly0%6

Other serious18.3%19,443

Not serious63.5%67,504

Patient age

Under 20%41

2 to 110%14

12 to 170%10

18 to 440.9%987

45 to 6413.7%14,509

65 to 7416%16,990

75 and over22.6%24,005

Age not given46.8%49,704

Who reported

Physician10.1%10,740

Pharmacist3.5%3,688

Other health professional8%8,461

Lawyer0%6

Consumer or non-health professional70.5%74,937

Not given7.9%8,428

Grey bar: all 20,646,523 reports in the database. Outcome flags are as the reporter set them and are not verified by FDA.

Questions about Parathyroid hormone analog reports

Which drugs are in the Parathyroid hormone analog class on this site?

Forteo and Teriparatide. Class membership comes from the pharmacologic class (EPC) on the drug's FDA label.

How many reports does the class have?

106,260 reports through June 2026, 1,837 of them in the latest 12 months. A report listing two drugs of the class counts once for each.

What reactions are recorded most often?

nausea (8.1%), arthralgia (7.9%), pain in extremity (7.6%), dizziness (7.5%) and fall (7.1%).

Can the members table be used to rank the drugs?

No. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." Drugs differ in how many people take them, in the conditions they treat, in time on the market and in how diligently reports are collected.

How do I report an adverse event?

Through FDA MedWatch (Form FDA 3500, or 1-800-FDA-1088) or to the manufacturer. See the guide on how to report.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A class is the Established Pharmacologic Class most often attached to a drug's reports by openFDA's label harmonisation, or from the NDC Directory where reports carry none. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.